Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine
08:08am, Friday, 26'th Aug 2022
Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Mod
Pfizer And Moderna Are In A Race With Omicron; Will The Vaccine Stocks Be Too Late?
07:45am, Friday, 26'th Aug 2022
Companies are working to develop updated Covid boosters. Will they be too late to make a difference for the vaccine stocks — and society?
1 Bear Market Blunder Investors Are Still Making
02:07pm, Thursday, 25'th Aug 2022 The Motley Fool
Focusing on the short term could lead to long-term losses.
Omicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorization
10:30am, Thursday, 25'th Aug 2022 MarketWatch
Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day, according to a new report.
1 Bear Market Blunder Investors Are Still Making
10:07am, Thursday, 25'th Aug 2022
Focusing on the short term could lead to long-term losses.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Morphic
09:52am, Thursday, 25'th Aug 2022 Zacks Investment Research
Pfizer, BioNTech, Moderna and Morphic are included in this Analyst Blog.
Pfizer (PFE), BioNTech Post Data on COVID Jab for Kids Under 5
04:40pm, Wednesday, 24'th Aug 2022 Zacks Investment Research
Pfizer (PFE) and BioNTech (BNTX) report updated data, showing that their three-dose COVID-19 vaccine is 73.2% effective in children under five years.
Moderna (MRNA) Seeks FDA Nod for Omicron-Based COVID Jab
04:27pm, Wednesday, 24'th Aug 2022 Zacks Investment Research
Moderna's (MRNA) bivalent COVID-19 booster vaccine, mRNA-1273.222, is designed to target the Omicron BA.4 and BA.5 subvariants. The vaccine has been developed specifically for the U.S. market.
Moderna (MRNA) Seeks FDA Nod for Omicron-Based COVID Jab
01:32pm, Wednesday, 24'th Aug 2022
Moderna's (MRNA) bivalent COVID-19 booster vaccine, mRNA-1273.222, is designed to target the Omicron BA.4 and BA.5 subvariants. The vaccine has been developed specifically for the U.S. market.
The S&P 500 Has Pulled Back From Its August Peak. Moderna, Carnival, and Match Are Part of the Blame.
10:50am, Wednesday, 24'th Aug 2022
Investors have pulled back from the stock market in the wake of downbeat economic data, as they wait for commentary from the Federal Reserve on Friday.
Omicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorization
10:06am, Wednesday, 24'th Aug 2022
Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day, according to a new report.
Omicron-specific boosters could be rolled out after Labor Day: report
12:46am, Wednesday, 24'th Aug 2022 MarketWatch
The New York Times reported Tuesday night that the Biden administration is eager to approve the new boosters as soon as possible, and is close to authorizing the updated shots.
These Are The Top 10 Holdings Of Patrick Degorce
07:41pm, Tuesday, 23'rd Aug 2022
Patrick Degorce is the founder and chief executive officer (CEO) of Theleme Partners.
Moderna (MRNA) to Supply Omicron-based COVID Jab in Canada
04:43pm, Tuesday, 23'rd Aug 2022 Zacks Investment Research
Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.
Moderna completes FDA submission for new COVID-19 booster
04:42pm, Tuesday, 23'rd Aug 2022
Moderna Inc. MRNA, +0.92% said late Tuesday it has completed its submission to the U.S. Food and Drug Administration for the emergency-use authorization for its experimental bivalent COVID-19 booster
